Molecular Classification of Lobular Carcinoma of the Breast

Overview

Journal Sci Rep

Specialty Science

Date 2017 Mar 18

PMID 28303886

Citations 6

Authors

Denggang Fu

Qi Zuo

Qi Huang

Li Su

Huijun Z Ring

Brian Z Ring

Affiliations

Soon will be listed here.

Abstract

The morphology of breast tumors is complicated and diagnosis can be difficult. We present here a novel diagnostic model which we validate on both array-based and RNA sequencing platforms which reliably distinguishes this tumor type across multiple cohorts. We also examine how this molecular classification predicts sensitivity to common chemotherapeutics in cell-line based assays. A total of 1845 invasive breast cancer cases in six cohorts were collected, split into discovery and validation cohorts, and a classifier was created and compared to pathological diagnosis, grade and survival. In the validation cohorts the concordance of predicted diagnosis with a pathological diagnosis was 92%, and 97% when inconclusively classified cases were excluded. Tumor-derived cell lines were classified with the model as having predominantly ductal or lobular-like molecular physiologies, and sensitivity of these lines to relevant compounds was analyzed. A diagnostic tool can be created that reliably distinguishes lobular from ductal carcinoma and allows the classification of cell lines on the basis of molecular profiles associated with these tumor types. This tool may assist in improved diagnosis and aid in explorations of the response of lobular type breast tumor models to different compounds.

Citing Articles

The combined signatures of the tumour microenvironment and nucleotide metabolism-related genes provide a prognostic and therapeutic biomarker for gastric cancer.

Liu J, Zhong L, Deng D, Zhang Y, Yuan Q, Shang D Sci Rep. 2023; 13(1):6622.

PMID: 37095256 PMC: 10126105. DOI: 10.1038/s41598-023-33213-z.

Uterine metastasis of lobular breast carcinoma under tamoxifen therapy: A case report.

Awazu Y, Fukuda T, Imai K, Yamauchi M, Kasai M, Ichimura T Mol Clin Oncol. 2021; 15(6):266.

PMID: 34777802 PMC: 8581738. DOI: 10.3892/mco.2021.2428.

A nomogram for determining the disease-specific survival in invasive lobular carcinoma of the breast: A population study.

Fu R, Yang J, Wang H, Li L, Kang Y, Kaaya R Medicine (Baltimore). 2020; 99(43):e22807.

PMID: 33120801 PMC: 7581138. DOI: 10.1097/MD.0000000000022807.

Applications of single cell RNA sequencing to research of stem cells.

Zhang X, Liu L World J Stem Cells. 2019; 11(10):722-728.

PMID: 31692946 PMC: 6828599. DOI: 10.4252/wjsc.v11.i10.722.

Feature Selection for Longitudinal Data by Using Sign Averages to Summarize Gene Expression Values over Time.

Tian S, Wang C Biomed Res Int. 2019; 2019:1724898.

PMID: 31016185 PMC: 6444255. DOI: 10.1155/2019/1724898.

References

DiCostanzo D, Rosen P, Gareen I, Franklin S, Lesser M . Prognosis in infiltrating lobular carcinoma. An analysis of "classical" and variant tumors. Am J Surg Pathol. 1990; 14(1):12-23. DOI: 10.1097/00000478-199001000-00002. View

Korkola J, DeVries S, Fridlyand J, Hwang E, Estep A, Chen Y . Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003; 63(21):7167-75. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Petit T, Wilt M, Velten M, Millon R, Rodier J, Borel C . Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004; 40(2):205-11. DOI: 10.1016/s0959-8049(03)00675-0. View

Tibshirani R, Hastie T, Narasimhan B, Chu G . Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002; 99(10):6567-72. PMC: 124443. DOI: 10.1073/pnas.082099299. View

West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R . Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A. 2001; 98(20):11462-7. PMC: 58752. DOI: 10.1073/pnas.201162998. View

Rieger-Christ K, Pezza J, Dugan J, BRAASCH J, Hughes K, Summerhayes I . Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol Pathol. 2001; 54(2):91-7. PMC: 1187009. DOI: 10.1136/mp.54.2.91. View

Liem X, Baranzelli M, Penel N, Giard S, Bonneterre J . Is adjuvant chemotherapy useful in lobular breast cancer patients?. Ann Oncol. 2011; 22(11):2532-2533. DOI: 10.1093/annonc/mdr312. View

Gunther K, Merkelbach-Bruse S, Amo-Takyi B, Handt S, Schroder W, Tietze L . Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol. 2001; 193(1):40-7. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH745>3.0.CO;2-N. View

10.

Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini K . Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. PLoS One. 2013; 8(8):e66848. PMC: 3747186. DOI: 10.1371/journal.pone.0066848. View

11.

Castellana B, Escuin D, Perez-Olabarria M, Vazquez T, Munoz J, Peiro G . Genetic up-regulation and overexpression of PLEKHA7 differentiates invasive lobular carcinomas from invasive ductal carcinomas. Hum Pathol. 2012; 43(11):1902-9. DOI: 10.1016/j.humpath.2012.01.017. View

12.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

13.

Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A . ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25(8):1091-3. PMC: 2666812. DOI: 10.1093/bioinformatics/btp101. View

14.

Barnard M, Boeke C, Tamimi R . Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015; 1856(1):73-85. DOI: 10.1016/j.bbcan.2015.06.002. View

15.

Arpino G, Bardou V, Clark G, Elledge R . Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004; 6(3):R149-56. PMC: 400666. DOI: 10.1186/bcr767. View

16.

Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M . Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol. 1990; 136(1):219-27. PMC: 1877466. View

17.

Berx G, Cleton-Jansen A, Strumane K, de Leeuw W, Nollet F, VAN Roy F . E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996; 13(9):1919-25. View

18.

Bland K, Menck H, Morrow M, Winchester D, WINCHESTER D . The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998; 83(6):1262-73. DOI: 10.1002/(sici)1097-0142(19980915)83:6<1262::aid-cncr28>3.0.co;2-2. View

19.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

20.

Newman L, Buzdar A, Singletary S, Kuerer H, Buchholz T, Ames F . A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002; 9(3):228-34. DOI: 10.1007/BF02573059. View